Bard Diagnostic's bladder cancer test cleared by FDA:
This article was originally published in Clinica
Executive Summary
Bard Diagnostic Sciences, a division of CR Bard, has received clearance from the FDA to market its BTA stat test in the US. The test detects bladder cancer with the technology found in one-step pregnancy tests. The company estimates that the test could benefit an estimated 48 million smokers in the US. Smokers experience twice the risk of bladder cancer as nonsmokers. Bladder cancer strikes almost 53,000 people in the US each year, and more than 250,000 people are routinely monitored for the disease, estimates the American Cancer Society.